These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30589503)

  • 1. Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant.
    Shelton BA; Berdahl G; Sawinski D; Linas BP; Reese PP; Mustian MN; Reed RD; MacLennan PA; Locke JE
    Am J Transplant; 2019 Jun; 19(6):1806-1819. PubMed ID: 30589503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.
    Shelton BA; Sawinski D; Linas BP; Reese PP; Mustian M; Hungerpiller M; Reed RD; MacLennan PA; Locke JE
    Am J Transplant; 2018 Oct; 18(10):2483-2495. PubMed ID: 30058218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list.
    Roth D; Bloom R
    Contrib Nephrol; 2012; 176():66-76. PubMed ID: 22310782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.
    Eckman MH; Woodle ES; Thakar CV; Paterno F; Sherman KE
    Ann Intern Med; 2018 Aug; 169(4):214-223. PubMed ID: 29987322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
    Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.
    Locke JE; Mehta S; Sawinski D; Gustafson S; Shelton BA; Reed RD; MacLennan P; Bolch C; Durand C; Massie A; Mannon RB; Gaston R; Saag M; Overton T; Segev DL
    Clin J Am Soc Nephrol; 2017 Mar; 12(3):467-475. PubMed ID: 28232406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
    AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
    Sawinski D; Lee DH; Doyle AM; Blumberg EA
    Transplantation; 2017 May; 101(5):974-979. PubMed ID: 27467534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study.
    Bahirwani R; Barin B; Olthoff K; Stock P; Murphy B; Rajender Reddy K;
    Liver Transpl; 2013 Jun; 19(6):619-26. PubMed ID: 23512786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients.
    Verlinden W; Bourgeois S; Gigase P; Thienpont C; Vonghia L; Vanwolleghem T; Michielsen P; Francque S
    J Ultrasound Med; 2016 Jun; 35(6):1299-308. PubMed ID: 27151906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    Durier N; Yunihastuti E; Ruxrungtham K; Kinh NV; Kamarulzaman A; Boettiger D; Widhani A; Avihingsanon A; Huy BV; Syed Omar SF; Sanityoso A; Chittmittrapap S; Dung NT; Pillai V; Suwan-Ampai T; Law M; Sohn AH; Matthews G
    J Viral Hepat; 2017 Mar; 24(3):187-196. PubMed ID: 27917597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.
    Malagnino V; Bottero J; Miailhes P; Lascoux-Combe C; Girard PM; Zoulim F; Lacombe K; Boyd A
    J Med Virol; 2019 Apr; 91(4):630-641. PubMed ID: 30431661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
    Burra P; Rodríguez-Castro KI; Marchini F; Bonfante L; Furian L; Ferrarese A; Zanetto A; Germani G; Russo FP; Senzolo M
    Transpl Int; 2014 Sep; 27(9):877-91. PubMed ID: 24853721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    Mandorfer M; Neukam K; Reiberger T; Payer BA; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Meyer-Olson D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M
    AIDS; 2013 Nov; 27(17):2707-14. PubMed ID: 23835502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.